CG Oncology (CGON) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CG Oncology (CGON) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 64.2% versus a gain of 28.6%. CG Oncology is the larger company by market cap ($5.53 billion vs $3.06 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | DNLI |
|---|---|---|
| Share price | $62.38 | $19.16 |
| Market cap | $5.53B | $3.06B |
| 1-day change | -1.98% | -0.62% |
| YTD return | +50.24% | +16.05% |
| 1-year return | +64.16% | +28.59% |
| 5-year return | — | -57.95% |
| EPS (TTM) | $-2.69 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $0 |
| Revenue growth (YoY) | +254.70% | — |
| Net income (latest FY) | $-161.00M | $-512.54M |
| Operating margin | -4722.13% | — |
| Net margin | -3985.02% | — |
| 52-week high | $80.97 | $27.30 |
| 52-week low | $35.80 | $13.75 |
| Distance from 52-week high | -22.96% | -29.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.01% | +88.20% |
| Average volume | 891.79K | 1.61M |
| Shares outstanding | 88.64M | 159.85M |
| Employees | 142 | 503 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGON has outperformed DNLI by 35.6 percentage points over the past year.
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Healthcare · Biotechnology · 142 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Healthcare · Biotechnology · 503 employees
CGON vs DNLI FAQ
Which is bigger, CG Oncology or Denali Therapeutics?
CG Oncology (CGON) is larger, with a market capitalization of $5.53B compared with $3.06B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, CGON or DNLI?
CGON returned +64.16% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Denali Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.